Dr. Martens’ main shareholder sells part of its shares
The Luxembourg company IngreLux, owned by funds advised by the private equity firm Permira, has announced that it has sold 65 million of its ordinary shares, at the price of 4.73 euros
This allowed the company to raise a total turnover of 257 million British pounds (307.7 million euros). According to shoeintelligence.com, the price represents a 6% discount from the previous day’s closing price, but is above the price set for Dr. Martens’ initial public offering in January 2021. Then, the iconic footwear brand had been valued at 4.2 billion euros.
IngreLux will hold, henceforth, a 36.4% stake in the British footwear company, which will not receive any proceeds from the placing. Barclays Bank and Goldman Sachs acted as joint bookrunners for the placing.
The market responded negatively to the news: Dr. Martens’ share price dropped almost 11%.
Image Credits: lechti.com
Related news
Related Events
Related Organizations
-
-
Footwear Consumer 2030
A study reflecting on the main global consumer trends and the key changes for the footwear industry.
-
World Footwear Public Calendar
Click here to subscribe an updated version of the calendar displaying the footwear trade shows.
-
-
-
Media Partners
Media Partners
-
Schuhkurier
La Conceria
Fotoshoe
Shoes Report